Comparative Pharmacology
Head-to-head clinical analysis: CARDAMYST versus TIAZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDAMYST versus TIAZAC.
CARDAMYST vs TIAZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARDAMYST is a monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), increasing LDL receptor availability and enhancing hepatic clearance of low-density lipoprotein cholesterol (LDL-C).
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
Intravenous loading dose of 150 mg, followed by continuous intravenous infusion at 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours. Oral maintenance therapy: 1 mg twice daily.
Oral: 120-360 mg once daily; maximum 540 mg daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Renal 70% (30% unchanged, 40% as inactive metabolites), biliary 20% (unchanged and metabolites), fecal 10%.
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker